Effective April 15, patients may bring one visitor to an appointment.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Disease Types: Cholangiocarcinoma,&nbs

Available at: {clinical_trial_location backspace="7"}Infigratinib vs Gem/Cis Cholangio, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}